Recruiting

Testing two medications together for blood cancers resistant to standard drugs

Plain-English translation of NCT06218628 on ClinicalTrials.gov ↗ · Source last updated May 2024 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage safety study testing whether and work better when given together to treat certain blood cancers (myeloproliferative neoplasms) that no longer respond to standard JAK2 inhibitor drugs. The research team will gradually increase doses of while keeping at a standard dose to find the safest and most effective combination. This is a Phase I trial, meaning it is primarily focused on understanding how safe these medications are when combined.

Many patients with these blood cancers stop responding to their first-line treatment or cannot tolerate it. This trial explores whether combining two different medications might help patients whose current drugs are no longer working, offering a new hope for people who have limited treatment options.

Do you qualify?

You likely qualify if…

you have been diagnosed with one of several types of myeloproliferative neoplasms (primary myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, chronic myelomonocytic leukemia, polycythemia vera, or essential thrombocytosis)
you have taken a JAK2 inhibitor for at least 12 weeks and your disease has progressed, or you cannot tolerate it
you are age 18 or older with adequate organ function and a good overall health status
you have significant symptoms from your blood cancer, as measured by a standard symptom assessment form
you have intermediate-2 or high-risk disease based on a prognostic scoring system
you are willing to have a bone marrow biopsy at the start of treatment and potentially additional biopsies during the study

You likely don't qualify if…

you have unresolved side effects from previous cancer treatment (except for certain types like nerve damage or hair loss)
your blood cancer has transformed into acute myeloid leukemia
you have an uncontrolled serious medical condition such as heart failure, an active infection, or another active cancer
you have a history of bleeding problems or uncontrolled bleeding
you are pregnant, breastfeeding, or taking certain other experimental medications

What participation looks like

You will start taking (one week before the official study start) and then add starting on day 1 of your first treatment cycle. Each treatment cycle lasts 28 days. The dose of will depend on which group you are assigned to, but it typically ranges from a low starting dose that may be increased over time. You will need to come for study visits, have blood work and bone marrow biopsies performed regularly (at the end of each cycle), and report any side effects to your research team. The study continues as long as the treatment is working and you are tolerating it well.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(1 site)

United States

Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania